Mast Therapeutics announces top-line Phase III trial data of vepoloxamer to treat sickle cell disease

US-based biopharmaceutical company Mast Therapeutics has reported top-line data from its Phase III EPIC study of vepoloxamer (MST-188) to treat patients with sickle cell disease experiencing vaso-occlusive crisis (VOC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news